Misplaced Pages

Applied Genetic Technologies Corporation

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Biotechnology company
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article reads like a press release or a news article and may be largely based on routine coverage. Please help improve this article and add independent sources. (October 2017)
The topic of this article may not meet Misplaced Pages's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.
Find sources: "Applied Genetic Technologies Corporation" – news · newspapers · books · scholar · JSTOR (October 2017) (Learn how and when to remove this message)
(Learn how and when to remove this message)
Applied Genetic Technologies Corporation
Company typePublic
Traded asNasdaq: AGTC
Russell Microcap Index component
IndustryBiotechnology
FoundedJanuary 19, 1999; 25 years ago (1999-01-19)
HeadquartersAlachua, Florida, United States
Key people
Revenue
  • Decrease US$ 24.19 million
  • (FY JUN 30, 2018)
Operating income
  • Decrease US$ -22.38 million
  • (FY JUN 30, 2018)
Net income
  • Decrease US$ -21.30 million
  • (FY JUN 30, 2018)
Total assets
  • Decrease US$ 118.53 million
  • (FY JUN 30, 2018)
Total equity
  • Decrease US$ 99.18 million
  • (FY JUN 30, 2018)
Number of employees
  • 78
  • (FY JUN 30, 2018)
WebsiteAGTC.com
Footnotes / references

The Applied Genetic Technologies Corporation is a publicly traded biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida. In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer.

The company focuses on ophthalmologic genetic diseases. The company's technologies are aimed at products that might have the potential to treat achromatopsia, X-linked retinoschisis, X-linked retinitis pigmentosa, and age-related macular degeneration. The company has six products in various stages of development; as of 2016, none had yet been approved.

In January 2017, AGTC entered into a strategic research and development collaboration with Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding. Through the collaboration, AGTC and Bionic Sight will to develop a new optogenetic therapy that leverages AGTC's deep experience in gene therapy and ophthalmology.

On January 9, 2020, the company reported positive results from a Phase 1/2 trial for its investigational gene therapy for retinitis pigmentosa. A few weeks later, the company reported interim six-month data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical programs in patients with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes. Applied Genetic Technologies Corporation is a patient partner within the blinding eye disease and rare disease community, including organizations like Foundation for Fighting Blindness and Global Genes.

References

  1. "US SEC: Form 10-K Applied Genetic Technologies Corporation". U.S. Securities and Exchange Commission. September 11, 2018. Retrieved December 1, 2018.
  2. "Applied Genetic Technologies Corporation (AGTC)". NASDAQ.com. Retrieved 4 January 2016.
  3. "Company Overview of Applied Genetic Technologies Corporation". Bloomberg. Retrieved November 15, 2016.
  4. "AGTC Announces New Leadership Appointments". Applied Genetic Technologies Corporation. Retrieved 2020-03-26.
  5. Chen, Angela. "Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments". Wall Street Journal. Retrieved 4 January 2016.
  6. "AGTC Announces Data Evaluating the Natural History of Patients With X-Linked Retinoschisis at the 48th Annual Retina Society Meeting". Yahoo Finance. Retrieved 4 January 2016.
  7. "Biogen enters eye-treatment arena with AGTC deal". Reuters. 2 July 2015. Retrieved 4 January 2016.
  8. Ballie, Katherine. "Penn-Michigan State Team Develops Novel Gene Therapy for Achromatopsia". www.upenn.edu. Archived from the original on 27 October 2015. Retrieved 4 January 2016.
  9. "Finding Cures for Visual Disorders l Products". www.agtc.com. Archived from the original on 5 January 2016. Retrieved 4 January 2016.
  10. "Collaborations". agtc.com. Retrieved 2020-03-13.
  11. Lee, Jaimy. "Applied Genetic Technologies' stock rockets on early-stage eye therapy data". MarketWatch. Retrieved 2020-02-25.
  12. "AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia". Applied Genetic Technologies Corporation. Retrieved 2020-03-04.
  13. "Patient Partners". agtc.com. Retrieved 2020-04-02.

External links


Stub icon

This United States corporation or company article is a stub. You can help Misplaced Pages by expanding it.

Categories: